Industrial chemical found in Cubicin

Apr 10, 2008

The U.S. Food and Drug Administration said Cubist Pharmaceuticals is warning that an industrial chemical has been found in the antibiotic Cubicin.

Cubist, a Massachusetts-based drug maker, said the chemical 2-mercaptobenzothiazole (MBT) has been found in reconstituted Cubicin stored in ReadyMED pumps, which are made by Cardinal Health. "At this time, Cubist recommends against using ReadyMED elastomeric infusion pumps with Cubicin," Cubist said in a letter to medical professionals last week.

Cubist spokeswoman Eileen McIntyre told The Wall Street Journal the company thinks the contamination came from the drug pumps. Cardinal Health said it is investigating the issue.

Cubist said MBT, which is used in the manufacturing of rubber, was not detected in samples from Eclipse pumps or control samples. The chemical has been associated with an increased risk of tumors in laboratory rats, Cubist said.

Copyright 2008 by United Press International

Explore further: Expression of privilege in vaccine refusal

add to favorites email to friend print save as pdf

Related Stories

New study charts the global invasion of crop pests

1 hour ago

Many of the world's most important crop-producing countries will be fully saturated with pests by the middle of the century if current trends continue, according to a new study led by the University of Exeter.

Zambia lifts ban on safari hunting

3 hours ago

Zambia has lifted a 20-month ban on safari hunting because it has lost too much revenue, but lions and leopards will remain protected, the government said Wednesday.

Recommended for you

Expression of privilege in vaccine refusal

11 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments : 0